Our Trials

Haematology Clinical Trial Unit - Current  open to recruitment trials

For more information Please contact:
Lisa Demosthenous
Haematology Clinical Trial Unit Manager
Lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182

Prof Constantine (Con) Tam, MBBS, MD, FRACP, FRCPA
Director of Haematology
constantine.tam@svha.org.au

A/Prof  Hang Quach MBBS (Hons) SpecCertOC FRACP FRCPA MD
Consultant Clinical and Laboratory Haematologist
hang.quach@svha.org.au

 

AbbVie M15-522 - MDS (Venetoclax/Aza) | A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure
 
AbbVie M15-654 | A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
 
ALLG HD10 |Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
 
AMaRC 03-16 VCDD vs VCD | A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
 
Amgen 20160445 | A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety,Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma
 
Amgen20140286 - Subcut Blinatumomab | A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma
  
APML5 | A phase I pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia (ALLG APML5 study) OPEN Jan
 
AUSTIN 1st FLOR | First-line treatment for grade 1-3A Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR study.
 
BGB311_AU_003 (monotherapy) | A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies
 
BGB3111_212 (FL) | An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
 
BGB3111_304 (TN CLL) | An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
 
BOSTON (KCP-330-023) Selinexor | A Phase 3 Randomized, Controlled, Open-Label Study Of Selinexor, Bortezomib, And Dexamethasone (Svd) Versus Bortezomib And Dexamethasone (Vd) In Patients With Relapsed Or Refractory Multiple Myeloma (RRMM)

 

Genentech GO29781 | An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

 
GSK205678 (DREAMM 2) | A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
 
GSK207497  (DREAMM 6) | A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma
 
KappaMab (HLX-KM-03) | A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma
 
Millennium  C16029 (RRMM) | A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)
 
Karyopharm (KCP-330-023) Selinexor (BOSTON) | A Phase 3 Randomized, Controlled, Open-Label Study Of Selinexor, Bortezomib, And Dexamethasone (Svd) Versus Bortezomib And Dexamethasone (Vd) In Patients With Relapsed Or Refractory Multiple Myeloma (RRMM)
 
M15-522 - MDS (Venetoclax/Aza) | A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure
 
MM19 | A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy
 
MRDR Registry | Myeloma & Related Diseases Registry
 
Myeloma 1000 Registry | The Myeloma 1000 Project 
 
NBCR | Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)
 
NHL29 | IRiC trial: a Phase II study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL. 
 
PCYC1143 | Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
 
ROCHE NP39403 (BET Inhibitor) | Open-Label, Multicenter, Dose-Escalation/Expansion Phase Ib Study To Evaluate Safety, Pharmacokinetics, And Activity Of Bet Inhibitor Ro6870810, Given As Mono- And Combination Therapy To Patients With Advanced Multiple Myeloma
 

TG-1701-110 | A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies

TREATT | TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia. A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe thrombocytopenia.